- Acne
- Actinic Keratosis
- Aesthetics
- Alopecia
- Atopic Dermatitis
- Buy-and-Bill
- COVID-19
- Case-Based Roundtable
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Drug Watch
- Eczema
- General Dermatology
- Hidradenitis Suppurativa
- Melasma
- NP and PA
- Pediatric Dermatology
- Pigmentary Disorders
- Practice Management
- Precision Medicine and Biologics
- Prurigo Nodularis
- Psoriasis
- Psoriatic Arthritis
- Rare Disease
- Rosacea
- Skin Cancer
- Vitiligo
- Wound Care
Article
Chronic HD responds to bexarotene gel
Portland, OR - In a small study of bexarotene gel treatment for chronic severe hand dermatitis (HD), the medication achieved both speedy and surprising results. In a 55-patient, phase 1-2 open-label randomized clinical study of the gel, used alone and in combination with one of two steroids, 79 percent of patients on monotherapy achieved clinical improvement of at least 50 percent, and 39 percent reached at least 90 percent clearance.
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Related Videos
What Dermatologists Need to Know About the Future of Regenerative Aesthetics
Redefining Anti-Aging with Regenerative Aesthetics and Growth Factor Skincare
Bridging the Communication Gap Between Providers and Patients Through the Skin Quality Index
Allergan Aesthetics' Effort to Create a Unified Vocabulary for Skin Quality
Optimizing Laser Therapy for Vascular Anomalies: Why Early Multidisciplinary Care Matters
Insights From the ADORING 3 Study and Tapinarof’s Treatment-Free Periods in AD
Tattoo Ink Risks, MultiFrax Laser, and the Impact of GLP-1 Medications on Skin Health
How Mindy Haws, MD, Empowers Women in Aesthetic Medicine
LIMITLESS: A Collaborative Effort Between Allergan, The Aesthetic Society, and The American Society of Plastic Surgeons
How the LIMITLESS Initiative Supports Female Leaders in Dermatology
Related Content
